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The spinal muscular atrophies (SMAs) include a group of disor-
ders characterized by progressive weakness of the lower motor 
neurons. Several types of SMAs have been described based on age 
onset of clinical features: Acute infantile (SMA type I), chronic in-
fantile (SMA type II), chronic juvenile (SMA type III), and adult 
onset (SMA type IV) forms. The incidence is about 1:6,000 live 
births with a carrier frequency of 1:40 for the severe form and 
1:80 for the juvenile form. The mortality and/or morbidity rates 
of SMAs are inversely correlated with the age at onset. SMAs are 
believed to only affect skeletal muscles; however, new data on 
SMA mice models suggest they may also impact the heart. 
Aim of the study was to retrospectively examine the cardiological 
records of 37 type molecularly confirmed II/III SMA patients, 
aged 6 to 65 years, in order to evaluate the onset and evolution 
of the cardiac involvement in these disorders. All patients had a 
standard ECG and a routine echocardiography. The parameters 
analysed were the following: Heart rate (HR), PQ interval, PQ 
segment,  Cardiomyopathic  Index  (ratio  QT/PQs),  ventricular 
and supraventricular ectopic beats, pauses ≥ 2,5msec, ventricle 
diameters,  wall  and  septum  thickness,  ejection  fraction,  fiber 
shortening. 
The results showed that HR and the other ECG parameters were 
within the normal limits except for the Cardiomyopathic Index 
that was higher than the normal values (2,6-4,2) in 2 patients. 
Left ventricular systolic function was within the normal limits in 
all patients. A dilation of the left ventricle without systolic dys-
function was observed in only 2 patients, aged respectively 65 
and 63 years; however they were hypertensive and/or affected by 
coronary artery disease. Data here reported contribute to reas-
sure patients and their clinicians that type II/III SMAs do not 
present heart dysfunction. 
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Background
Spinal muscular atrophies (SMAs) refer to a group of 
neuromuscular disorders characterized by degeneration of 
the anterior horn cells of the spinal cord, leading to weak-
ness of the lower motor neurons and progressive muscu-
lar atrophy. Several types of SMAs have been described 
based on age onset of clinical features: Acute infantile 
(SMA type I), Chronic infantile (SMA type II), Chronic 
juvenile (SMA type III), and Adult onset (SMA type IV) 
forms (1). The incidence is about 1:6,000 live births with 
a mean carrier frequency of 1:50. The mortality and/or 
morbidity rates of SMAs are inversely correlated with 
the age at onset. Deletions in the survival motor neuron 
(SMN) gene (5q11.2-5q13.3) are the major determinants 
of SMA phenotype (2-9) while deletions in the neuronal 
apoptosis inhibitory protein (NAIP) gene may correlate 
with the severity of SMA (10-12).
Humans express a copy gene, SMN2, from the same 
region of chromosome 5q as a result of duplication and 
inversion. SMN2 is nearly identical to SMN1 (2-4); how-
ever, mutations in SMN2 have no clinical consequence 
if intact SMN1 is present. The reason that SMN2 can-
not fully complement the SMN1 deficiency is that the 
majority  of  SMN2-derived  transcripts  are  alternatively 
spliced (5-7), leading to a truncated and unstable protein 
that lacks the 16 amino acids encoded by SMN exon 7 
(normally the last coding exon) (3, 5, 8-12). 
Symptoms range from congenital hypotonia to dif-
ferent  degree  of  muscle  weakness,  contractures,  fas-
ciculations,  scoliosis  and  absence  of  tendon  reflex-
es (1, 10, 14).
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Based  on  our  current  knowledge  of  SMA,  motor 
neurons are the primary tissue affected in SMA. How-
ever there are clinical reports suggesting that other tissues 
contribute to the overall phenotype, especially in the most 
severe forms of the disease. Upon autopsy, a growing 
number of congenital heart defects have been recognized, 
including atrial septal defects, dilated right ventricle (RV) 
and ventricular septal defects. The most common defect 
is an anomalous development of the heart, referred to as 
hypoplastic left heart syndrome (15-18). In juvenile type 
of SMA, cases presenting malignant ventricular arrhyth-
mia or bundle-branch or atrioventricular blocks have been 
reported needing prophylactic dual-chamber cardioverter 
defibrillator or pacemaker implantation (19-23). However 
the authors suggest that such findings are probably pro-
voked by pulmonary and respiratory anomalies, under-
lining the importance of correct respiratory assistance to 
prevent the onset of cardiological alterations.
Furthermore new data on SMA mice models suggest 
that the heart may be also impacted (24-26). These findings 
reveal a new area of investigation that will be important to 
address as we move towards emerging treatment options 
for spinal muscular atrophy, followed by clinical success. 
Aim of the study was to retrospectively examine the 
cardiological records of 37 type II/III SMA patients, aged 
6 to 65 years, to evaluate the onset and evolution of the 
cardiac involvement in these disorders.
Patients and methods
The records of 37 patients with SMA type II/III (mean 
age at the enrolment 23.3 ± 15.5 years) diagnosed at the 
Cardiomyology  and  Medical  Genetics,  Second  Naples 
University in the period from 1990 and 2010, were ret-
rospectively re-examined in order to assess the onset and 
evolution of cardiac involvement. The diagnosis of Spinal 
muscular atrophy, firstly based on clinical and electro-
neurological findings was subsequently confirmed in all 
patients by molecular analysis of SMN gene.
Cardiac function has been yearly evaluated by stand-
ard ECG and Mono, 2D- and Echocolor-doppler-cardi-
ography. When the basic ECG revealed arrhythmias, the 
patients underwent dynamic 24h Holter monitoring. The 
following electrocardiographic parameters were analysed: 
heart rate (HR), PQ interval (PQi, n.v. 0,12-0,20msec), PQ 
segment (PQs), QT interval (QTi, n.v. 0,30-0,40 msec), 
Cardiomyopathic Index (ratio QT/PQs, adjusted for HR, 
n.v. 2,6 – 4,2), T waves anomalies and presence of ectopic 
ventricular or supraventricular beats.
The  echocardiographic  parameters  evaluated  were 
the following: left ventricle diameters (DD, SD), inter-
ventricular septum thickness (IVS) and left ventricle free 
wall (LVFW) in mm, end-diastolic volume (EDV), end-
systolic volume (ESV) and cardiac output (CO) in ml. At 
the enrolment, all patients had a standard ECG and 31/37 
a routine echocardiography. The cardiological records at 
the last available control, were re-evaluated in 29 patients 
followed for periods ranging from 1.5 to 20 years. 
statistical analysis 
The observed values, expressed according to the age, 
height and weight of patients, are indicated as mean and 
standard deviation. Student T test for paired data was ap-
plied to evaluate differences between baseline and last con-
trol values. A p value < 0.05 was considered as significant.
results
The results are summarised in Tables 1 and 2. As re-
garding  the  electrocardiographic  parameters,  only  HR 
shows a decline with age, as expected. At the baseline, the 
table 1. Electrocarwdiographic parameters in type II/III spinal muscular atrophies patients.
Basic Values Values at the F.U. P value
N. of Patients 37 21
Mean age (range) 23.3 ± 15.5 29.0 ± 14.9
HR 83.25 ± 18.35 72.8 ± 11.5* 0.03
PQi in msec 0.13 ± 0.03 0.14 ± 0.02 n.s.
PQs in msec 0.04 ± 0.01 0.04 ± 0.01 n.s.
QT in msec 0.35 ± 0.03 0.36 ± 0.03 n.s.
Cardiomyopathic Index 3.38 ± 0.74 3.93 ± 0.67 0,05
Mean Follow-up in years 11.4 ± 8.6
* P value < 0.05Heart and SMA
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other parameters were within the normal limits except for 
the Cardiomyopathic Index that presented higher values in 
2 patients. Echocardiographic parameters were within the 
normal limits in all patients. A dilation of the left ventricle 
without systolic dysfunction, was observed in only 2 pa-
tients, aged respectively 65 and 63 year; however they were 
hypertensive and/or  affected by coronary artery disease.
Discussion
The most severe form of SMA presents with clear 
symptoms at birth, and usually die within 2 years. As 
these patients have the lowest SMN levels as well as 
SMN2 copy number, they are the most likely to show 
defects in cells other than the motor neuron. Cardiac in-
volvement has been described in patients with type 1 
Spinal Muscular Atrophy who present since birth a high 
degree of pulmonary involvement, with acute respirato-
ry failure often leading to the needs of invasive tracheal 
ventilatory assistance. In these cases heart involvement 
could be secondary to respiratory insufficiency. A few 
key studies regarding SMA patients have implicated the 
involvement of cardiovascular and autonomic nervous 
systems. A retrospective study of type 1 SMA patients 
identified that 15/63 SMA patients experienced symp-
tomatic bradycardia (15). Although it is clear that SMA 
is a neurodegenerative disease, there are clinical reports 
suggesting that other tissues contribute to the overall 
phenotype, especially in the most severe forms of the 
disease.  
A  retrospective  study  on  43  patients,  age  range  3 
months to 3 years, 37 of which presented type I (Werdnig-
Hoffmann disease) and 6 type II (intermediate form dis-
ease), performed by Distefano et al. (15) showed that no 
clinical nor instrumental signs of cardiomyopathy were 
observed. However, ECG revealed signs of right ventricu-
lar overload in 37.3% of the patients, probably provoked 
by pulmonary hypertension due to respiration anomalies.
On the other hand, few cardiological studies mainly 
concern subjects affected by the juvenile form (Kugel-
berg-Welander disease) (19-23). The presence of a car-
diomyopathy has been reported in these patients but the 
cardiac involvement is often described as secondary to 
the chronic respiratory insufficiency typical of the dis-
ease. 
Three papers recently appeared in the literature (24-
26) focus the attention on arrhythmias and cardiac defects 
as a feature of spinal muscular atrophy model mice. They 
find that a severe model of SMA mice suffer from se-
vere brady-arrhythmia characterized by progressive heart 
block and impaired ventricular depolarization. Further in-
vestigations showed evidence of both sympathetic inner-
vation defects and dilated cardiomyopathy at late stages 
of disease. Pathological responses including fibrosis and 
oxidative stress markers were additionally observed short-
ly after birth in a less severe model of disease (24-28). 
Data  here  reported  confirm  our  previous  observa-
tions (31) that at least types II/III SMA do not present 
primary  heart  dysfunction.  These  observations,  while 
confirming SMA patients should be evaluated regularly 
for cardiac disease, nevertheless they contribute to reas-
sure patients and their clinicians on the use of experi-
mental drugs, potentially contraindicated in cardiopathic 
patients.
table 2. Ecocardiographic parameters in type II/III Spinal Muscular Atrophy patients.
Basic Values Values at the last control P value
N° of Patients 29 19
Mean age (range) 17.2 ± 14.8 28.9 ± 15.1
DD in mm 43.6 ± 8.7 46.8 ± 7.0 n.s.
SD in mm 28.1 ± 6.3 30.1 ± 4.8 n.s.
IVS in mm 8.4 ± 2.0 9.4 ± 1.2 n.s.
LVFW in mm 8.6 ± 1.9 9.5 ± 1.0 n.s.
EDV in ml 91.5 ± 33.6 104.8 ± 36.4 n.s.
ESV in ml 32.2 ± 14.2 36.7 ± 14.7 n.s.
CO in ml 61.2 ± 20.6 65.4 ± 22.3 n.s.
EF in% 66.4 ± 4.8 65.3 ± 2.5 n.s.
FS in% 36.7 ± 3.4 36.0 ± 1.8 n.s.
Mean Follow-up in years 12.3 ± 9.3
* P < 0.05Alberto Palladino et al.
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